ABOUT  |  NEWS  |  PRODUCTS  |  TECHNOLOGY  |  INVESTOR RELATIONS  |  CAREER

The Scientific Advisory Board


 

Prof. Dr. Burghardt Wittig, Germany

Co-founder and former CEO of MOLOGEN AG

Professor for molecular biology and bioinformatics at the Freie Universität Berlin

 

Prof. Dr. Hans Lutz, FVH, FAMH, Switzerland

Professor for clinical laboratory diagnostics and head of the veterinary medicinal laboratory and vice dean of planning and resources, Vetsuisse faculty, University of Zurich

 

Dr. Ulrich Granzer, Germany

Founder and CEO of Granzer Regulatory Consulting & Services, Munich

 

Dr. med. habil. Martin Weihrauch, Germany

Board certified Internist, Hematologist and Oncologist at the Center for Intergrated Oncology and Medical Director of the outpatient department (MVZ) at the University Clinic, Cologne

 

Prof. Dr. Farrokh Modabber, Ph.D., Switzerland

Senior Manager at Drugs for Neglected Diseases initiative (DNDi), Geneva

 

NEWS

June 22, 2010

MOLOGEN AG receives approval for clinical study with cell-based gene therapy against renal cancer


  press release

  ad-hoc announcement

June 22, 2010

MOLOGEN AG starts phase 2 clinical study with DNA-based cancer medicine MGN1703 against colorectal cancer


  more

NEWSLETTER

To subscribe to our Newsletter please

 click here

REPORTS

To view our Reports

  click here